Liver Disease Newco Alentis Raises CHF12.5m Series A

A syndicate of European VCs commits CHF12.5m to Alentis Therapeutics a Swiss-French start-up with a discovery platform focusing on liver diseases. Lead program is a humanized monoclonal antibody targeting liver fibrosis and hepatocellular carcinoma.

Liver cancer, CT scan upper abdomen.
Advanced liver disease and cancer are major clinical challenges

Swiss venture capital firms BioMedPartners and BB Pureos Bioventures have co-led a CHF12.5m ($12.3m) series A round in Alentis Therapeutics, a Swiss-French newco, that is looking to develop novel therapeutics in advanced liver disease and cancer. Other investors in the syndicate are BPI France, Schroder Adveq and the German High-Tech Gründerfonds. Markus Ewert, formerly CBO at Ablynx NV, has been appointed CEO of the new company, which will be headquartered in Basel, Switzerland with a subsidiary in Strasbourg, France and a branch in Germany.

Incubated for the past 18 months by SATT Connectus, the tech transfer accelerator associated with the Alsace region, Alentis is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category